Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy-Reference-Cited by-同舟云学术

Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy

Published:2021-12 Issue: Volume: Page:
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Chong Benjamin F.^ORCID,Werth Victoria^ORCID

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference81 articles.

1. Efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis. Results of a randomized, double-blind, placebo-controlled phase III trial (ProDERM study);Aggarwal;Arthritis Rheumatol,2020

2. Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis;Ahmed;Br J Dermatol,2020

3. The CLASI (Cutaneous LE Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus;Albrecht;J Invest Dermatol,2005

4. Dermatology position paper on the revision of the 1982 ACR criteria for SLE [published correction appears in Lupus 2005;14:178];Albrecht;Lupus,2004

5. Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus;AlE'ed;Lupus Sci Med,2018

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Spectrum of Cutaneous Manifestations in Lupus Erythematosus: A Comprehensive Review;Journal of Clinical Medicine;2024-04-21

2. Clinical aspects of cutaneous lupus erythematosus;Frontiers in Medicine;2023-01-09

3. Baricitinib for the treatment of cutaneous dermatomyositis: A prospective, open-label study;Journal of the American Academy of Dermatology;2022-12

4. Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist;The Journal of Rheumatology;2022-09-15